Table 1 Clinicopathological characteristics of enrolled breast cancer patients after surgery

Type of surgery

0.712

0.837

 Mastectomy

105(87.6%)

208(84.6%)

81(92.0%)

158(89.8%)

 Breast conserving surgery

11(9.1%)

26(10.6%)

5(5.7%)

13(7.4%)

 Other

4(3.3%)

12(4.8%)

2(2.3%)

5(2.8%)

Chemotherapy regimen

0.851

0.452

 AC-T

60(50.0%)

130(52.8%)

44(50%)

102(57.9%)

 TCb

45(37.5%)

85(34.6%)

28(31.8%)

49(27.9%)

 Other

15(12.5%)

31(12.6%)

16(18.2%)

25(14.2%)

Histology

0.804

0.976

 Infiltrative ductal

90(75.0%)

183(74.4%)

67(76.1%)

132(75.0%)

 Infiltrative lobular

22(18.3%)

50(20.3%)

17(19.4%)

36(20.5%)

 Other

8(6.7%)

13(5.3%)

4(4.5%)

8(4.5%)

Tumor size

0.527

0.693

 ≥ 2 cm

18(15.0%)

31(12.6%)

10(11.4%)

23(13.1%)

 < 2 cm

102(85.0%)

215(87.4%)

78(88.6%)

153(86.9%)

Number of tumors

0.266

0.650

 1

110(91.7%)

216(87.8%)

81(92.0%)

159(90.3%)

 > 1

10(8.3%)

30(12.2%)

7(8.0%)

17(9.7%)

Grade of histology

0.704

0.929

 I

6(5.0%)

15(6.1%)

4(4.5%)

9(5.1%)

 II

70(58.3%)

151(61.4%)

49(55.7%)

101(57.4%)

 III

44(36.7%)

80(32.5%)

35(39.8%)

66(37.5%)

Lymphovascular invasion

0.382

0.702

 Yes

80(66.7%)

175(71.1%)

61(69.3%)

126(71.6%)

 No

40(33.3%)

71(28.9%)

27(30.7%)

50(28.4%)

Radiotherapy

0.137

0.512

 Yes

72(60.0%)

167(67.9%)

58(65.9%)

123(69.9%)

 No

48(40.0%)

79(32.1%)

30(34.1%)

53(30.1%)

Hormone therapy

0.346

0.467

 Yes

75(62.5%)

166(67.5%)

54(61.4%)

116(65.9%)

 No

45(37.5%)

80(32.5%)

34(38.6%)

60(34.1%)

ER/PR

0.346

0.467

 Positive

75(62.5%)

166(67.5%)

54(61.4%)

116(65.9%)

 Negative

45(37.5%)

80(32.5%)

34(38.6%)

60(34.1%)

HER2

0.269

0.492

 Positive

35(29.2%)

86(35.0%)

26(29.5%)

45(25.6%)

 Negative

85(70.8%)

160(65.0%)

62(70.5%)

131(74.4%)

Ki67

0.164

0.330

 ≥ 30%

63(52.5%)

148(60.2%)

56(63.6%)

101(57.4%)

 < 30%

57(47.5%)

98(39.8%)

32(36.4%)

75(42.6%)

Molecular subtype

0.640

0.765

 Hormone receptor positive

67(55.8%)

150(61.0%)

54(61.4%)

116(65.9%)

 Triple negative

25(20.9%)

46(18.7%)

15(17.0%)

27(15.3%)

 HER2 positive

28(23.3%)

50(20.3%)

19(21.6%)

33(18.8%)

N stage

0.685

0.994

 0

50(41.7%)

109(44.3%)

34(38.6%)

70(39.8%)

 1

31(25.8%)

71(28.9%)

27(30.7%)

55(31.3%)

 2

22(18.3%)

40(16.3%)

16(18.2%)

30(17.0%)

 3

17(14.2%)

26(10.5%)

11(12.5%)

21(11.9%)

T stage

0.903

0.937

 1

57(47.5%)

112(45.6%)

36(40.9%)

75(42.6%)

 2

55(45.8%)

115(46.7%)

47(53.4%)

90(51.1%)

 3

8(6.7%)

19(7.7%)

5(5.7%)

11(6.3%)

TNM stage

0.651

0.624

 1

20(16.7%)

51(20.7%)

14(15.9%)

35(19.9%)

 2

60(50.0%)

116(47.2%)

46(52.3%)

82(46.6%)

 3

40(33.3%)

79(32.1%)

28(31.8%)

59(33.5%)

Adverse reaction during chemotherapy [13]

 < 0.001

0.002

 Low

70(58.3%)

184(74.8%)

53(60.2%)

138(78.4%)

 High

50(41.7%)

62(25.2%)

35(39.8%)

38(21.6%)

Transaminase after chemotherapy

 ALT

87.830 ± 2.089

30.701 ± 2.262

 < 0.001

87.139 ± 2.731

30.246 ± 2.361

 < 0.001

 AST

71.945 ± 1.233

23.556 ± 1.048

 < 0.001

71.270 ± 1.113

23.107 ± 1.611

 < 0.001

Nausea and vomiting during chemotherapy

 < 0.001

0.023

 Yes

79(65.8%)

112(45.5%)

56(63.6%)

86(48.9%)

 No

41(34.2%)

134(54.5%)

32(36.4%)

90(51.1%)

Metastasis and recurrence

0.022

0.010

 Yes

38(31.7%)

51(20.7%)

28(31.8%)

39(22.2%)

 No

82(68.3%)

195(79.3%)

60(68.2%)

137(77.8%)

Treatment after recurrence and metastasis

0.986

0.364

 Conservative treatment

29(76.3%)

39(76.5%)

20(71.4%)

30(76.9%)

 Surgery

9(23.7%)

12(23.5%)

8(28.6%)

9(23.1%)

Survival status

0.030

 < 0.001

 Alive

92(76.7%)

211(85.8%)

70(79.5%)

150(85.2%)

 Dead

28(23.3%)

35(14.2%)

18(20.5%)

26(14.8%)